| Nov 5 |
Black Diamond: Q3 Earnings Snapshot
|
| Nov 5 |
Black Diamond Therapeutics GAAP EPS of -$0.28 beats by $0.09
|
| Nov 5 |
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks
|
| Nov 5 |
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 1 |
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
|
| Oct 8 |
Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data
|
| Oct 7 |
Black Diamond CFO departs as part of restructuring, job cuts
|
| Oct 7 |
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
|
| Sep 23 |
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
|
| Sep 23 |
Black Diamond reports encouraging Phase 2 data for BDTX-1535
|
